GNSZ Stock UPDATES Genspera Inc (GNSZ) 0.7900 09/23/2014 19:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genspera Inc (GNSZ) 0.7900 $GNSZ

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)

Genspera Wins Summary Judgment in Mhaka Litigation
PR Newswire - Thu Sep 18, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

GenSpera Receives Patent on Prodrug Targeted for Prostate Cancer
PR Newswire - Tue Sep 09, 7:20AM CDT
GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company's presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.

Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)

GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization
PR Newswire - Wed Sep 03, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association.

GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids
PR Newswire - Thu Aug 28, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids.

GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Thu Aug 14, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer
PR Newswire - Wed Jul 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available
PR Newswire - Tue Jul 22, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and investors.

Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).

GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
PR Newswire - Tue Jul 15, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5th Asia-Pacific Primary Liver Cancer Expert Meeting Saturday, July 12th, in Taipei, Taiwan.

Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
PR Newswire - Mon Jul 14, 8:20AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.

GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei
PR Newswire - Mon Jul 07, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13th in Taipei, Taiwan.

Media Advisory: GenSpera 2014 BIO International Presentation Available
PR Newswire - Mon Jun 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.

Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)

GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
PR Newswire - Tue Jun 24, 3:27PM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"
PR Newswire - Mon Jun 23, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 30

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 101

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 62

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Experiences Coming to Myrtle Beach in 2025

Updated Category News Views 1799

Discover What's New and Exciting in Myrtle Beach Fresh, unique adventures await at The Beach. As one of the Southeast's most beloved travel destinations, Myrtle Beach is gearing up for an exciting new year filled with unforgettable new and expanded experiences, alongside its iconic offerings that continue to draw visitors to its golden shores from across the nation. With...

Continue Reading
NXP Semiconductors Showcases Strong Energy and Growth Initiatives

Updated Category News Views 250

NXP Semiconductors Posts Impressive Q3 2025 Financial Results NXP Semiconductors N.V. (NASDAQ: NXPI) has announced its financial results for the third quarter, revealing a revenue of $3.17 billion. This performance exceeded market expectations and places NXP in a strong position amidst improving economic conditions. The company's president, Rafael Sotomayor, highlighted...

Continue Reading
Red Pine Exploration Secures Significant Funding Through Placement

Updated Category News Views 81

Red Pine Exploration Announces Major Funding Initiative Today, Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) has captured attention with its announcement of a significant C$7.0 million private placement. This deal, arranged by Haywood Securities Inc. and Research Capital Corporation, sets the stage for the company’s growth while bolstering its gold exploration...

Continue Reading
Ken Griffin Critiques Trump's Tariff Policies Impacting Economy

Updated Category News Views 172

Ken Griffin's Strong Critique of Tariff Policies Ken Griffin, known as the CEO of Citadel LLC, has emerged as a vocal critic of former President Donald Trump's tariff policy, labeling it as detrimental to the American economy. Griffin's stance marks a significant shift from his previous support for Trump, and he is urging for a reevaluation of the existing economic...

Continue Reading
Investigation Launched into Spyre Therapeutics by Pomerantz

Updated Category News Views 175

Pomerantz LLP Investigates Spyre Therapeutics, Inc. Pomerantz LLP is currently conducting an investigation on behalf of investors in Spyre Therapeutics, Inc. (NASDAQ: SYRE). This investigation seeks to uncover whether the company, along with its officials and directors, has engaged in fraudulent activities or other illicit business practices. Investors who believe they...

Continue Reading